Monday April 16, 2001

COMPANY PRESS RELEASE

Transgenomic Announces Gregory Duman as Chief Financial Officer and William Rasmussen Moves to Business Development

SAN JOSE, Calif., and OMAHA, Neb., Apr. 16 /PRNewswire/ -- Transgenomic, Inc. (Nasdaq: TBIO) announced today that Gregory J. Duman has joined the company as executive vice president of finance and administration and chief financial officer. The company also announced the repositioning of William P. Rasmussen into a strategic planning capacity working directly with Collin D'Silva, chairman of the board and chief executive officer.

Most recently, Duman served as chief financial officer of Artios, Inc, a privately-held provider of transaction processing services. Prior to joining Artios, Duman was executive vice president and chief financial officer of Transaction Systems Architects, Inc. He joined TSA in 1983 as director of administration, was promoted to controller in 1985, and became chief financial officer in 1991. From 1999 through 2000 he served the dual role of CFO and head of software product development. Prior to his time at TSA, Duman worked for Arthur Andersen & Co. as a certified public accountant from 1979 to 1983.

Duman has served on the board of directors of Transgenomic since March 2000, and will continue in that capacity. He is also currently a director on the boards of Transactions Systems Architects and Digital Courier Technologies, Inc.

D'Silva commented, "This addition and repositioning strengthens our management team. Greg Duman brings an outstanding background in financial management to our company and will play a primary role in helping to keep us at the forefront of our industry. And Bill Rasmussen's historical involvement with Transgenomic's goals, objectives and position in the industry make him uniquely qualified to assist with the execution of our business development strategy."

About Transgenomic

Transgenomic is headquartered in Omaha, Neb., and has offices in the United States, Europe and Japan. Major research and development facilities are located in San Jose, Calif., and Crewe, Cheshire, United Kingdom. The company provides innovative research tools to the genomics segment of the life sciences industry. These tools enable researchers to discover and understand variation in the human genetic code, or genome, in order to accelerate and improve drug development and diagnostics.

Forward Looking Statement

This press release may contain forward-looking statements that reflect management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results. Such statements are subject to certain factors, risks and uncertainties described from time to time in Transgenomic, Inc.'s reports to the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2000, which was filed with the Commission on March 16, 2001. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release.

For more information, contact: